Literature DB >> 10741803

Correlation between plasma carnitine, muscle carnitine and glycogen levels in maintenance hemodialysis patients.

A Kawecka, K Wojnarowski, J Prajs, S Malgorzewicz, D Kunicka, Z Zdrojewski, J Lipiński, B Rutkowski.   

Abstract

Chronic hemodialysis (HD) may lead to losses of carnitine from plasma and muscle. Plasma carnitine does not reflect the body content of carnitine. The purpose of this study was the evaluation of total and free plasma and muscle carnitine concentrations (TPC, FPC, TMC, FMC), muscle glycogen and the relationship between plasma and tissue carnitine content and the basic indices of lipid metabolism in HD patients. The studies were conducted in two groups: the first one consisted of 37 HD patients (19 F, 18 M), the second one served as the control and was composed of 29 (10 F, 19 M) patients with healthy kidneys. Tissue specimens in HD patients were taken during surgery on arterio-venous fistula from brachioradial muscle. Carnitine and glycogen measurements were performed using enzymatic methods according to Cederblad and Huijng respectively. Total cholesterol (CH), HDL-CH, and triglycerides were assayed by enzymatic commercial test system (Boehringer-Mannheim, Germany). To summarise, we found the following phenomena in our HD patients in comparison with the controls: 1) In plasma: similar TPC but decreased FPC levels and FPC/TPC ratio which may suggest free carnitine deficiency. 2) In muscle: significantly lower TMC and FMC levels but normal FMC/ITMC ratio. 3) Negative correlation between TMC and FMC levels and duration of dialysis treatment. 4) No correlation between plasma and muscle camitine concentration. 5) Significantly higher concentration of muscle glycogen which could be explained by the changes in the structure of muscle fibres in HD patients and/or lower physical activity. 6) A positive correlation between FPC/APC or FPC/TPC ratio and HDL-CH in HD patients which may suggest that an appropriate proportion between free and acylcarnitines may influence HDL-CH levels in that population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741803

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  9 in total

Review 1.  The use of levo-carnitine in children with renal disease: a review and a call for future studies.

Authors:  Brook Belay; Nora Esteban-Cruciani; Christine A Walsh; Frederick J Kaskel
Journal:  Pediatr Nephrol       Date:  2005-12-23       Impact factor: 3.714

Review 2.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

3.  Carnitine supplementation improves cardiac strain rate in children on chronic hemodialysis.

Authors:  Kristen Sgambat; Lowell Frank; Ahmad Ellini; Craig Sable; Asha Moudgil
Journal:  Pediatr Nephrol       Date:  2012-03-22       Impact factor: 3.714

4.  L-carnitine supplementation and EPO requirement in children on chronic hemodialysis.

Authors:  Bilal Aoun; Etienne Bérard; Renata Vitkevic; Axelle Dehée; Albert Bensman; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2009-08-07       Impact factor: 3.714

5.  A pharmacokinetic model for L-carnitine in patients receiving haemodialysis.

Authors:  Gianfranco Fornasini; Richard N Upton; Allan M Evans
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

Review 6.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Mass Spectrometric Analysis of L-carnitine and its Esters: Potential Biomarkers of Disturbances in Carnitine Homeostasis.

Authors:  Judit Bene; Andras Szabo; Katalin Komlósi; Bela Melegh
Journal:  Curr Mol Med       Date:  2020       Impact factor: 2.222

Review 8.  Significance of Levocarnitine Treatment in Dialysis Patients.

Authors:  Hiroyuki Takashima; Takashi Maruyama; Masanori Abe
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

Review 9.  Mitochondria: a new therapeutic target in chronic kidney disease.

Authors:  Simona Granata; Alessandra Dalla Gassa; Paola Tomei; Antonio Lupo; Gianluigi Zaza
Journal:  Nutr Metab (Lond)       Date:  2015-11-25       Impact factor: 4.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.